Clinical Evidence

CLINICAL RESULTS: Absence of undesired effects.
Absence of interruptions in radiochemotherapy treatment.

CLINICAL RESULTS:
Treated patients with Mucosamin Spray developed less severe mucositis. Treated patients with Mucosamin Spray resolved the mucositis in less time. Maximum pain, measured with VAS scale, was lower in patients treated with Mucosamin Spray.

CLINICAL RESULTS:
Treated patients with Mucosamin Spray developed less severe mucositis.
Treated patients with Mucosamin Spray resolved the mucositis in less time.
Maximum pain, measured with VAS scale, was lower in patients treated with Mucosamin Spray.

CLINICAL RESULT
Reduction of the onset of oral mucositis. Reduction of the severity of oral mucositis. The mouthwash in prevention and the spray in treatment are a valuable therapeutic aid for oral mucositis in patients undergoing HSCT.

CLINICAL RESULT
Application of Mucosamin® vaginal cream during VBT was shown to have clinical benefit for FIGO* stage I endometrial cancer patients who received adjuvant HDR-VBT following surgery.
It appears to reduce the severity of mucosal reactions.
Optimal resolution of actinic vaginitis symptoms.

CLINICAL RESULTS:
Significantly promote patients’ healing and compliance.
Reduce pain sensation.
A more frequent improvement in mucosal objectivity already in the short term.
Mucosamin seems improve the degree of satisfaction, especially among females.

CLINICAL RESULTS: Appearence of G1 cutaneous erythema in patient treated with Radioderm® Spray occurred at the 18th session on average compared to those treated with placebo (12th session on average). Radioderm® Spray helped delay the appearence of G1 cutaneous toxicity.